Correlation Between Unicycive Therapeutics and RAYTHEON

Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and RAYTHEON at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and RAYTHEON into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Unicycive Therapeutics and RAYTHEON TECHNOLOGIES PORATION, you can compare the effects of market volatilities on Unicycive Therapeutics and RAYTHEON and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of RAYTHEON. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and RAYTHEON.

Diversification Opportunities for Unicycive Therapeutics and RAYTHEON

-0.52

Correlation Coefficient

Unicycive Therapeutics  RAYTHEON

Excellent diversification

The 3 months correlation between Unicycive and RAYTHEON is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and RAYTHEON TECHNOLOGIES PORATION in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on RAYTHEON TECHNOLOGIES and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with RAYTHEON. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of RAYTHEON TECHNOLOGIES has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and RAYTHEON go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and RAYTHEON

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 2.39 times more return on investment than RAYTHEON. However, Unicycive Therapeutics is 2.39 times more volatile than RAYTHEON TECHNOLOGIES PORATION. It trades about 0.21 of its potential returns per unit of risk. RAYTHEON TECHNOLOGIES PORATION is currently generating about 0.08 per unit of risk. If you would invest  55.00  in Unicycive Therapeutics on September 24, 2024 and sell it today you would earn a total of  13.00  from holding Unicycive Therapeutics or generate 23.64% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	95.24%
Values	Daily Returns

Unicycive Therapeutics  vs.  RAYTHEON TECHNOLOGIES PORATION

Unicycive Therapeutics

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

RAYTHEON TECHNOLOGIES

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days RAYTHEON TECHNOLOGIES PORATION has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, RAYTHEON is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Unicycive Therapeutics and RAYTHEON

The main advantage of trading using opposite Unicycive Therapeutics and RAYTHEON positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, RAYTHEON can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in RAYTHEON will offset losses from the drop in RAYTHEON's long position.

The idea behind Unicycive Therapeutics and RAYTHEON TECHNOLOGIES PORATION pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.